Source: MarketScreener

Soligenix: Soligenix Announces Phase 3 FLASH Study Continues to Demonstrate Positive Benefits in Patients with Cutaneous T-Cell Lymphoma

(marketscreener.com) PRINCETON, N.J., Oct. 22, 2020 /PRNewswire/ -- Soligenix, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that continued optional treatment with SGX301 across all lesions during the compassionate use, safety...https://www.marketscreener.com/news/latest/Soligenix-Announces-Phase-3-FLASH-Study-Continues-to-Demonstrate-Positive-Benefits-in-Patients-with--31591734/?utm_medium=RSS&utm_content=20201022

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Christopher J. Schaber's photo - Chairman & CEO of Soligenix

Chairman & CEO

Christopher J. Schaber

CEO Approval Rating

88/100

Soligenix is a late-stage biopharmaceutical company that researches and develops novel vaccines for the treatment of cancer and infectious diseases. Read more